Previous Close | 20.20 |
Open | 19.87 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's Range | 20.20 - 20.20 |
52 Week Range | 16.65 - 22.12 |
Volume | |
Avg. Volume | 1,316 |
Market Cap | 82.538B |
Beta (5Y Monthly) | 0.27 |
PE Ratio (TTM) | 13.56 |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | 0.80 (3.97%) |
Ex-Dividend Date | Feb 22, 2024 |
1y Target Est | N/A |
PHILADELPHIA, March 16, 2024--RUBY phase III data show potential for Jemperli (dostarlimab-gxly) combinations in more patients with primary advanced or recurrent endometrial cancer
PHILADELPHIA, March 07, 2024--GSK doubles COiMMUNITY grant funding, launches patient resources, as adult vaccination rates begin to show promising rise
GSK (GlaxoSmithKline Inc.) has submitted a Supplementary New Drug Submission (SNDS) to Health Canada to expand the use of Arexvy, GSK's respiratory syncytial virus (RSV) vaccine (recombinant, AS01E adjuvanted), to include adults aged 50-59 at increased risk for RSV disease. If approved, GSK's RSV vaccine would be the first vaccine available in Canada to help protect this population.